Commentary and thoughts on health care
- Republicans have indicated that they are willing to work with democrats on drug pricing initiatives.
- Drug companies are focusing lobbying efforts to use a possible lame-duck session of Congress to peel back a legislative loss they suffered earlier this year.
- Pharma is making a lobbying push to roll back seniors’ drug discounts at a time when they are reporting near record profits.
- So far in 2018, PhRMA spent more than $20 million, according to the Center for Responsive Politics, and was the third-largest spender.